EUCTR2009-017094-38-IT
Active, Not Recruiting
N/A
Gene expression as predictive markers of outcome in non-small cell lung cancer patients (stage IIIB with pleural effusion and stage IV) treated with chemotherapy. Phase II trial of GOIRC. - ND
GRUPPO ONCOLOGICO ITALIANO DI RICERCA0 sitesNovember 2, 2010
Conditionspatients with non-small cell lung cancer cells in stage IIIB (with supraclavicular lymphnode metastases and / or pleural effusion) or IV, not previously treated with chemotherapy for advanced diseaseMedDRA version: 9.1Level: SOCClassification code 10029104
DrugsTAXOTERE
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- patients with non-small cell lung cancer cells in stage IIIB (with supraclavicular lymphnode metastases and / or pleural effusion) or IV, not previously treated with chemotherapy for advanced disease
- Sponsor
- GRUPPO ONCOLOGICO ITALIANO DI RICERCA
- Status
- Active, Not Recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histological or cytological confirmation of NSCLC Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy (Stage IIIB/IV) Samples for genetic research Age ≥ 18 years old and ≤ 72 or older ECOG PS 0\-1 Measurable (uni\-dimensional) disease by RECIST criteria in a lesion not previously irradiated or non\-measurable disease Absolute neutrophil count greater than 1\.5 x 109/L, platelet count greater than 100 x 109/L and haemoglobin greater than 10 g/dl Bilirubin level either normal or \<1\.5 x ULN, AST (SGOT) and ALT (SGPT) \<2\.5 x ULN Serum creatinine \<1\.5 x ULN or creatinine clearance \>60 ml/min Provision of written informed consent Effective contraception for both, male and female pts, if the risk of conception exists
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •No prior chemotherapy regimens Radiotherapy within 2 weeks of study entry or about target lesion Current infection Newly diagnosed CNS metastases that have not yet been treated with surgery and/or radiation. Pts with previously diagnosed and treated CNS metastases or spinal cord compression may be considered if they have evidence of clinically SD (no steroid therapy or steroid dose being tapered) for at least 28 days As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic or renal disease) Other co\-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study Positive pregnancy test
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
Evaluation of biomarkers and gene expression profile related to peripheral microvascular reserve in patients with severe infectionsRBR-10jksk74Hospital de Clínicas - Universidade Federal do paraná
Active, Not Recruiting
N/A
Evaluation of hand microvessel blood flow changes after transient obstruction in patients with infections associated with organ dysfunctionsSepsisMicrocirculationIschemiaVascular ResistanceBiomarkersGeneticsRBR-35tv9ftComplexo hospital de Clínicas da Universidade Federal do Paraná
Completed
N/A
Screening of biomarkers using gene expression profiling in peripheral blood of severely septic patientsSevere sepsisJPRN-UMIN000014502Graduate School of Medicine, Chiba University40
Unknown
N/A
Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast CancerBreast TumorNCT01247480National University Hospital, Singapore
Unknown
N/A
Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic SyndromeMyelodysplastic SyndromeNCT02330692Yonsei University1,000